Pfizer emerged victorious in the takeover battle for obesity‑drug developer Metsera, agreeing to an increased offer valuing the company at about $10 billion. The late‑stage bid ended a public bidding clash with Novo Nordisk that escalated into legal disputes and personnel maneuvers at both firms. Pfizer’s win consolidates its position in the obesity therapeutic landscape and resolves a high‑profile acquisition tussle that had drawn regulatory and market attention; the companies involved and terms were disclosed in corporate filings and press releases.